

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)



(10) International Publication Number
WO 2022/212510 A1

- (51) **International Patent Classification:**
G01N 21/17 (2006.01) *G01N 21/64* (2006.01)
- (21) **International Application Number:**
PCT/US2022/022556
- (22) **International Filing Date:**
30 March 2022 (30.03.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/169,568 01 April 2021 (01.04.2021) US
- (71) **Applicant:** MEDIBEACON INC. [US/US]; 1100 Corporate Square Drive, Helix Center, Suite 175, St. Louis, Missouri 63132 (US).
- (72) **Inventors:** TARR, Phillip I.; c/o MEDIBEACON INC., 1100 Corporate Square Drive, Helix Center, Suite 175, St. Louis, Missouri 63132 (US). DORSHOW, Richard B.; c/o
- MEDIBEACON INC., 1100 Corporate Square Drive, Helix Center, Suite 175, St. Louis, Missouri 63132 (US).
- (74) **Agent:** KREPEL, Allison N. et al.; POLSINELLI PC, 105 West Vandalia, Suite 400, Edwardsville, Illinois 62025 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) **Title:** METHODS OF MONITORING MUCOSAL HEALING




FIG. 1

(57) **Abstract:** The disclosure provides for methods for monitoring mucosal healing in a patient with a digestive disease, or for use in a pre-disease state and includes intestinal as well as extra-intestinal disorders in which gut permeability is increased. The method may include establishing a baseline of the patient, treating the patient for the digestive disease or the pre-disease state, measuring gut permeability of the patient after treatment, and comparing a second total percentage of the administered dose recovered to the baseline total percentage of the administered dose recovered.

[Continued on next page]



WO 2022/212510 A1

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*